Alzheimer's disease and acetylcholinesterase inhibitor agents: A two-year longitudinal study

Archives of Gerontology and Geriatrics

Volumn 38, Issue SUPPL., 2004, Pages 187-194

  Fuschillo, C ^a,b   Ascoli, E ^a   Franzese, G ^a   Campana, F ^a   Cello, C ^a   Galdi, M ^a   La Pia, S ^a   Cetrangolo, C ^a  

^a ASL NA 4   (Italy)

^b NONE   (Italy)

Author keywords

Acetylcholinesterase inhibitors; Alzheimer disease; CRONOS project; Unit of Evaluation for Alzheimer

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; RIVASTIGMINE;

ABDOMINAL PAIN; AGED; ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NAUSEA; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; VOMITING; BRAIN; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DAILY LIFE ACTIVITY; ELECTROCARDIOGRAPHY; MENTAL DISEASE; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; RADIOGRAPHY;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MENTAL DISORDERS; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 3042647043     PISSN: 01674943     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.archger.2004.04.026     Document Type: Article

References (36)

1. APA (American Psychiatric Association) (1994): Diagnostic and Statistical Manual of Mental Disorders. 4th ed., American Psychiatric Association, Washington, DC.
2. Auriacombe, S., Pere, J.-J., Loria-Kanza, Y. and Vellas, B. (2002): Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. Cur. Med. Res. Opin., 18, 129-138.
3. Bachman, D.L., Wolf, P.A., Linn, R., Knoefel, J.E., Cobb, J., Belanger, A., D'Agostino, R.B. and White, L.R. (1992): Prevalence of dementia and probable senile of the Alzheimer type in the Framinghan Study. Neurology, 42,115-119.
4. Bianchetti, A. and Trabucchi, M. (1997): I costi sociali delle demenze: Lo studio CO. DEM. Gior. Geront., 45, 605-612 (in Italian).
5. Bianchetti, A. and Trabucchi, M. (2001): Clinical aspects of Alzheimer's disease. Aging, 13, 221-230.
6. Bianchetti, A., Padovani, A., and Trabucchi, M. (2003): Outcome of Alzheimer's disease treatment: the Italian CRONOS project. Int. J. Geriatr. Psychiatry, 1, 87-88.
7. Bullock, R. and Connolly, C. (2002): Switching cholinesterase inhibitory therapy in Alzheimer's disease; donepezil to rivastigmine, is it worth? Int. J. Geriatr. Psychiatry, 17, 288-289.
8. Burns, A., Rossor, M., Hecker, J., Gauthier, S., Petit, H., Moller, H.J., Rogers, S.L. and Friedhoff, L.T. (1999): The effect of donepezil in Alzheimer's disease - results from a multinational trial. Dement. Geriatr. Cogn. Disord., 10 , 237-244.
9. Corey-Bloom, J., Anand, R. and Veach, J. for the ENA 713 B352 Study Group (1998): A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartarate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int. J. Geriatr. Pharmacol., 1, 55-65.
10. Cummings, J.L. and Cole, G. (2002): Alzheimer disease. J. Am. Med. Assoc., 18, 2335-2338.
11. Cummings, J.L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D.A. and Gombei, J. (1994): The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology, 44, 2308-2314.
12. Doody, R.S., Stevens, J.C., Beck, C., Dubinshy, R.M., Kaye, J.A., Gwyther, L., Mohs, R.C., Thal, L.J., Whitehouse, P.J., DeKosky, S.T. and Cummings, J.L. (2001): Practice parameter: Management of dementia (an evidence-based review). Report of the Standards Subcommittee of the American Academy of Neurology. Neurology, 56, 1154-1166.
13. Evans, D.A., Scherr, P.A., Cook, N.R., Albert, M.S., Funkenstein, H.H. and Smith, L.A. (1990): Estimated prevalence of Alzheimer's disease in the United States. Milbank Q., 68, 267 289.
14. Farlow, M., Anand, R., Messina, J. Jr., Hartman, R. and Veach, J. (2000): A 52-week study of the efticacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur. Neurol., 44, 234-241.
15. Friedhoff, L.T. and Rogers, S.L. (1997): Donepezil lengthens time to loss of activities of daily living in patients with mild to moderate Alzheimer's disease. Results of a preliminary evaluation. Neurology, 48 (Suppl. 3), A100 (anstract only).
16. Folstein, M.F., Folstein, S.E. and McHugh, P.R. (1975): Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res., 12, 189-198.
17. Fuschillo, C., La Pia, S., Campana, F., Pinto, A. and De Simone, L. (2001): Cognitive deficits in Alzheimer's disease: treatment with acetylcholinesterase inhibitor agents. Arch. Gerontol. Geriatr. Suppl. 7, 151-158.
18. Giacobini, E. (2001): Is anti-cholinesterase therapy of Alzheimer's disease delaying progression? Aging Clin. Exp. Res., 13, 247-254.
19. Grutzendler, J. and Morris J.C. (2001): Cholinesterase Inhibitors for Alzheimer's disease. Drugs, 61, 41-52.
20. Honing, L.S. and Mayeux, R. (2001): Natural history of Alzheimer's disease. Aging Clin. Exp. Res., 13, 171-182.
21. Katz, S., Ford, A.B., Moskowitz, R.W., Jackson, B.A. and Jaffe, M.W. (1963): Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. J. Am. Med. Assoc., 185, 914-919.
22. Knapp, M., Wilkinson, D. and Wigglesworth, R. (1998): The economic consequences of Alzheimer's disease in the context of new drug developments. Int. J. Geriatr. Psychiatry, 13, 531-543.
23. Krall, W.J., Sramek, I. and Cutler, N.R. (1999): Cholinesterase inhibitors: a therapeutic strategy for Alzheimer's disease. Ann. Pharmacother., 33, 441-450.
24. Lawton, M.P. and Brody, E.M. (1969): Assessment of older people: self-maintaining and instrumental activities of daily living. J. Am. Geriatr. Soc., 9, 179-186.
25. Magni, E., Binetti, G., Bianchetti, A., Rozzini, R. and Trabucchi, M. (1996): Mini-Mental State examination: a normative study in an Italian elderly population. Eur. J. Neurol., 3, 1-5.
26. McGleenon, B.M., Dynan, K.B. and Passmore, A.P. (1999): Acetylcholinesterase inhibitors in Alzheimer's disease. Br. J. Clin. Pharmacol., 48, 471-480.
27. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D. and Stadlan, E.M. (1984): Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health. Neurology, 34, 939-944.
28. Ministerial Decrete of 20th July, 2000 (2000): Protocollo di monitoraggio dei piani di trattamento farmacologico per la malattia di Alzheimer. G.U. Repubblica Italiana, Suppl. 204, 1-2 (in Italian).
29. Morris, J.C. (1994): Differential diagnosis in Alzheimer's disease. Clin. Geriatr. Med., 10, 257-276.
30. Pammolli, F., Malorgio, G., Turchetti, G. and Riccaboni, M. (1998): II costo sociale della Malattia di Alzheimer. Quaderni Centro Studi Economia e Sanitá. Business International, Vol. 7, (in Italian).
31. Raskind, M.A., Peskind, R., Wessel, T. and Yuan, W. (2000): Galantamine in Alzheimer's disease - a 6-month, randomised, placebo-controlled trial with a 6-month extension. Neurology, 54, 2261-2268.
32. Rocca, P., Cocuzza, E., Marchiaro, L., Bogetto, F. (2002): Donepezil in the treatment of Alzheimer's disease: long-term efficacy and safety. Prog. Neuropsychopharmacol. Biol. Psychiatry, 26, 369-373.
33. Rogers, S.L. (2000): Long-term, efficacy and safety of donepezil in the treatment of Alzheimer's Disease: final analysis of a US multicentre, open-label study. Eur. Neuropsychopharmacol., 10, 195-203.
34. Rogers, S.L., Farlow, M.R., Doody, R.S., Mohs, R.C., Friedoff, L.T. and the Donepezil Study Group (1998): A 24-week, double bind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology, 50, 136-145.
35. Winblad, B., Engedal, K., Soininen, H., Verhey, F., Waldemar, G., Wimo, A., Wetterholm, A.L., Zhang, R., Haglund, A., Subbiah, P. and Donepezil Nordic Study Group (2001): A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology, 57, 489-495.
36. Yesavage, J.A., Brink, T.L., Rose, T.L., Lum, O., Huang, V., Adey, M. and Leirer, V.O. (1982): Development and validation of a geriatric depression screening scale: a preliminary report. J. Psychiatr. Res., 17, 37-49.